Compare Organon & Co. Common Stock (OGN) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Oscar Health Inc — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Oscar Health Inc trades at $34.01 (market cap $10.59B). The key difference: Oscar Health Inc is far larger — about 2.9× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Oscar Health Inc for 15 Days on average.
| OGN | OSCR | |
|---|---|---|
Market Cap | $3.61B | $10.59B |
Volume | 1,808,049 | 5,280,571 |
Sector | Health | Health |
52-Week High | $13.81 | $34.32 |
52-Week Low | $5.70 | $10.85 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $11.03B | $6.95B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Oscar Health (OSCR) trades at $33.79, down 0.65% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company shows impressive revenue growth from $11.7B in 2025 to $15.3B projected for 2026, with profitability turning positive from a $443M loss to $551M net income. Recent earnings beats in Q1 and Q2 2026 exceeded expectations by significant margins, while analyst sentiment remains mixed with a $34.75 consensus target slightly above current levels.
OSCR presents a growth story with expanding market share in ACA plans and improved medical loss ratios, though profitability remains sensitive to medical cost trends. The stock faces near-term resistance at $35 with RSI suggesting potential overbought conditions. Key risks include execution on growth targets and healthcare cost pressures, while institutional interest remains strong with recent price target upgrades following positive guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
